IMPEL NEUROPHARMA INC's ticker is IMPL and the CUSIP is 45258K109. A total of 40 filers reported holding IMPEL NEUROPHARMA INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $0 | – | 109 | 0.0% | 0.00% | – |
| Q2 2023 | $0 | – | 109 | +45.3% | 0.00% | – |
| Q3 2022 | $0 | -100.0% | 75 | -82.4% | 0.00% | – |
| Q1 2022 | $3,000 | -76.9% | 426 | -70.2% | 0.00% | – |
| Q4 2021 | $13,000 | +62.5% | 1,431 | +102.7% | 0.00% | – |
| Q3 2021 | $8,000 | +166.7% | 706 | +90.8% | 0.00% | – |
| Q2 2021 | $3,000 | – | 370 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NVP Associates, LLC | 3,077,198 | $11,539,493 | 11.26% |
| Vivo Capital, LLC | 2,884,789 | $43,272 | 4.98% |
| venBio Partners LLC | 2,759,791 | $10,349,216 | 3.21% |
| 5AM Venture Management, LLC | 2,884,791 | $10,817,966 | 2.91% |
| LASRY MARC | 408,329 | $1,531,234 | 2.38% |
| DCF Advisers, LLC | 325,825 | $1,221,844 | 0.83% |
| Kohlberg Kravis Roberts & Co. L.P. | 4,135,971 | $15,509,891 | 0.52% |
| EPIQ PARTNERS, LLC | 18,646 | $69,923 | 0.05% |
| J. Goldman & Co LP | 200,219 | $750,821 | 0.04% |
| MCDONALD PARTNERS LLC | 11,700 | $43,875 | 0.02% |